Male Celebrities Reported to Use Ozempic
Public reports and interviews have identified several male celebrities using Ozempic for weight management or diabetes management. Elon Musk stated in 2022 that he lost weight using Wegovy and Ozempic, with his former partner confirming the use in interviews and on social media. Other male figures in entertainment and business have been linked to the drug through trainer statements, leaked messages, and reported clinic visits, though many have not publicly confirmed use. The trend reflects broader interest among high-net-worth individuals in GLP-1 receptor agonist therapies for body composition and metabolic health.
Media outlets including Forbes and Business Insider have reported on celebrity use patterns, noting that demand has driven shortages and increased scrutiny on off-label prescribing. Clinics in major U.S. cities have reported high-profile patients seeking compounded or brand-name versions, with some celebrities traveling across state lines for prescriptions. The visibility of these cases has contributed to a measurable increase in search volume and prescription rates among men aged 30 to 60, particularly in industries where physical appearance is closely tied to professional roles.
Ozempic Costs, Supply, and Company Data
Novo Nordisk, the manufacturer of Ozempic, has reported significant revenue growth tied to demand for its GLP-1 products. In its latest financial disclosures, the company noted that supply constraints have affected availability in the U.S., leading some patients and celebrities to seek alternative sourcing through compounding pharmacies or international markets. The cash price for a monthly supply of Ozempic in the U.S. has been reported in the range of 900 to 1,000 dollars without insurance, though manufacturer savings cards and insurance coverage can lower out-of-pocket costs for eligible patients.
Eli Lilly's competing GLP-1 drug tirzepatide, sold under the brand name Mounjaro for weight management, has also seen celebrity interest and rapid revenue growth. Reports indicate that some male celebrities have switched between Ozempic and Mounjaro based on availability, side effects, and physician guidance. Novo Nordisk's market capitalization has risen sharply on the back of GLP-1 demand, and the company has invested in expanding production capacity to meet global demand. Investors and analysts have closely tracked these developments as a key driver of pharmaceutical sector performance.
Regulatory and Market Impact of Celebrity Use
The FDA has issued warnings about counterfeit Ozempic and compounded versions lacking the active ingredient semaglutide, a risk amplified by high-profile demand. Celebrities sharing their experiences publicly have increased consumer interest, prompting the FDA and pharmacy boards to crack down on unregulated online sellers and questionable clinics. In parallel, health policy experts have raised concerns about equitable access, as celebrity and affluent demand can strain supply for patients using Ozempic for diabetes management.
Insurance coverage policies for GLP-1 drugs have evolved in response to rising demand, with some plans restricting coverage to diabetes diagnoses and requiring step therapy before approving weight-loss use. The SEC filings of Novo Nordisk and Eli Lilly highlight the financial significance of this market segment, with both companies citing GLP-1 products as a major growth driver. Publicly traded health insurers and pharmacy benefit managers have also reported margin impacts from the increased utilization of these medications. For more details on Novo Nordisk's financial outlook, see https://www.novonordisk.com/company/investors.html and for FDA guidance on compounded drugs, see https://www.fda.gov/drugs/compounding-faqs-regulatory-requirements-compounding-drugs-under-fda